logo

Cns Pharmaceuticals Inc (CNSP)



Trade CNSP now with
  Date
  Headline
6/23/2022 8:40:27 AM CNS Pharma Gets FDA Nod For Protocol Amendment To Potentially Pivotal Global Trial Of Berubicin For GBM
5/16/2022 8:07:47 AM CNS Pharma Q1 Net Loss $2.8 Mln Vs. Loss $3.6 Mln Prior Year
4/28/2022 8:45:00 AM CNS Pharma Receives Approval From Spain For Study Of Berubicin For Treatment Of Glioblastoma Multiforme
4/6/2022 8:37:36 AM CNS Receives Approval From France For Potentially Pivotal Study Of Berubicin For Treatment Of Glioblastoma Multiforme
4/5/2022 8:37:17 AM CNS Gets Approval From Switzerland For Potentially Pivotal Study Of Berubicin For Treatment Of Glioblastoma Multiforme
3/3/2022 8:41:53 AM CNS Pharma FY Net Loss $14.0 Mln Vs Loss $9.5 Mln Prior Year
1/6/2022 7:17:57 AM CNS Pharma Announces $11.5 Mln Private Placement Priced At-the-Market Under Nasdaq Rules
12/2/2021 8:37:30 AM CNS Gets Approval From Switzerland Ethics Committee For Potentially Pivotal Study Of Berubicin For Treatment Of GBM
9/30/2021 8:08:25 AM CNS Doses First Group Of Patients With Berubicin In Potentially Pivotal Study For Treatment Of Glioblastoma Multiforme
7/1/2021 9:06:45 AM CNS To Execute On Corporate, Regulatory Strategies To Drive Berubicin Towards Commercialization For Treatment Of GBM
6/29/2021 8:36:32 AM CNS Pharma: FDA Grants Fast Track Designation For Berubicin For Treatment Of Recurrent Glioblastoma Multiforme